Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Inactivation of Brca2 cooperates with Trp53(R172H) to induce invasive pancreatic ductal adenocarcinomas in mice: a mouse model of familial pancreatic cancer.

Feldmann G, Karikari C, dal Molin M, Duringer S, Volkmann P, Bartsch DK, Bisht S, Koorstra JB, Brossart P, Maitra A, Fendrich V.

Cancer Biol Ther. 2011 Jun 1;11(11):959-68. Epub 2011 Jun 1.

2.

Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma.

Rasheed ZA, Yang J, Wang Q, Kowalski J, Freed I, Murter C, Hong SM, Koorstra JB, Rajeshkumar NV, He X, Goggins M, Iacobuzio-Donahue C, Berman DM, Laheru D, Jimeno A, Hidalgo M, Maitra A, Matsui W.

J Natl Cancer Inst. 2010 Mar 3;102(5):340-51. doi: 10.1093/jnci/djp535. Epub 2010 Feb 17.

3.

Widespread activation of the DNA damage response in human pancreatic intraepithelial neoplasia.

Koorstra JB, Hong SM, Shi C, Meeker AK, Ryu JK, Offerhaus GJ, Goggins MG, Hruban RH, Maitra A.

Mod Pathol. 2009 Nov;22(11):1439-45. doi: 10.1038/modpathol.2009.114. Epub 2009 Aug 7.

4.

Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer.

Mullendore ME, Koorstra JB, Li YM, Offerhaus GJ, Fan X, Henderson CM, Matsui W, Eberhart CG, Maitra A, Feldmann G.

Clin Cancer Res. 2009 Apr 1;15(7):2291-301. doi: 10.1158/1078-0432.CCR-08-2004. Epub 2009 Mar 3.

5.

The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target.

Koorstra JB, Karikari CA, Feldmann G, Bisht S, Rojas PL, Offerhaus GJ, Alvarez H, Maitra A.

Cancer Biol Ther. 2009 Apr;8(7):618-26. Epub 2009 Apr 22.

6.

MicroRNA miR-155 is a biomarker of early pancreatic neoplasia.

Habbe N, Koorstra JB, Mendell JT, Offerhaus GJ, Ryu JK, Feldmann G, Mullendore ME, Goggins MG, Hong SM, Maitra A.

Cancer Biol Ther. 2009 Feb;8(4):340-6. Epub 2009 Feb 3.

7.

In vivo characterization of a polymeric nanoparticle platform with potential oral drug delivery capabilities.

Bisht S, Feldmann G, Koorstra JB, Mullendore M, Alvarez H, Karikari C, Rudek MA, Lee CK, Maitra A, Maitra A.

Mol Cancer Ther. 2008 Dec;7(12):3878-88. doi: 10.1158/1535-7163.MCT-08-0476.

8.

Undifferentiated carcinoma with osteoclastic giant cells (UCOCGC) of the pancreas associated with the familial atypical multiple mole melanoma syndrome (FAMMM).

Koorstra JB, Maitra A, Morsink FH, Drillenburg P, ten Kate FJ, Hruban RH, Offerhaus JA.

Am J Surg Pathol. 2008 Dec;32(12):1905-9. doi: 10.1097/PAS.0b013e31818371cd.

9.

An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer.

Feldmann G, Fendrich V, McGovern K, Bedja D, Bisht S, Alvarez H, Koorstra JB, Habbe N, Karikari C, Mullendore M, Gabrielson KL, Sharma R, Matsui W, Maitra A.

Mol Cancer Ther. 2008 Sep;7(9):2725-35. doi: 10.1158/1535-7163.MCT-08-0573.

10.

Establishment and characterization of a bona fide Barrett esophagus-associated adenocarcinoma cell line.

Alvarez H, Koorstra JB, Hong SM, Boonstra JJ, Dinjens WN, Foratiere AA, Wu TT, Montgomery E, Eshleman JR, Maitra A.

Cancer Biol Ther. 2008 Nov;7(11):1753-5. Epub 2008 Nov 4.

11.

Pancreatic carcinogenesis.

Koorstra JB, Hustinx SR, Offerhaus GJ, Maitra A.

Pancreatology. 2008;8(2):110-25. doi: 10.1159/000123838. Epub 2008 Apr 1. Review.

12.

Morphogenesis of pancreatic cancer: role of pancreatic intraepithelial neoplasia (PanINs).

Koorstra JB, Feldmann G, Habbe N, Maitra A.

Langenbecks Arch Surg. 2008 Jul;393(4):561-70. doi: 10.1007/s00423-008-0282-x. Epub 2008 Feb 19. Review.

Supplemental Content

Loading ...
Support Center